Skip to main content

Table 2 Biodistribution data of AAZTA-MG labelled with different radiometals 1 h p.i. in different mouse models

From: Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue

  111In-AAZTA-MG 68Ga-AAZTA-MG 177Lu-AAZTA-MG 68Ga-AAZTA-MG
CCK+/− BALB/c nude mice CCK+/− BALB/c nude mice BALB/c nude mice BALB/c nude mice
Blood 0.14 ± 0.03 0.38 ± 0.07 0.10 ± 0.09 2.90 ± 1.39
Spleen 0.14 ± 0.02 0.13 ± 0.01 0.11 ± 0.04 0.91 ± 0.34
Pancreas 0.13 ± 0.03 0.14 ± 0.02 0.12 ± 0.04 0.68 ± 0.28
Stomach 0.61 ± 0.11 0.47 ± 0.03 1.18 ± 0.13 0.95 ± 0.22
Intestine 8.62 ± 1.24 0.61 ± 0.08 19.14 ± 3.40 2.43 ± 0.32
Kidneys 1.79 ± 0.32 2.51 ± 0.66 1.39 ± 0.73 3.37 ± 0.43
Liver 2.46 ± 0.96 0.42 ± 0.07 3.05 ± 1.31 1.48 ± 0.26
Heart 0.12 ± 0.09 0.15 ± 0.04 0.07 ± 0.06 0.88 ± 0.32
Lung 0.21 ± 0.06 0.33 ± 0.07 0.14 ± 0.05 1.59 ± 0.47
Muscle 0.15 ± 0.18 0.07 ± 0.03 0.10 ± 0.17 0.36 ± 0.23
Femur 0.20 ± 0.11 0.11 ± 0.02 0.21 ± 0.18 0.74 ± 0.42
CCK2+ tumour (left flank) 1.74 ± 0.80 1.51 ± 0.53   
CCK2− tumour (right flank) 0.33 ± 0.11 0.44 ± 0.06   
  1. Data are shown as %ID/g (mean ± SD, n = 4)